GLP-1 receptor agonists like liraglutide show promise for reducing neuroinflammation alongside their blood sugar benefits, leveraging shared inflammatory pathways between diabetes and brain diseases.
Shared NLRP3 pathwayDiabetes and neuroinflammation share the NLRP3 inflammasome pathway, providing the biological basis for repurposing GLP-1 agonists and other diabetes drugs for brain diseases
What the researchers found
The review identifies several diabetes drugs with neuroinflammatory potential:
- Liraglutide (GLP-1 receptor agonist): Showed encouraging effects in regulating blood sugar while possibly lowering neuroinflammation; obese patients saw decreased neuroinflammatory markers alongside weight loss and glycemic improvements
- Gliburide (sulfonylurea): Effectively inhibits the NLRP3 inflammasome, suggesting potential for neuroinflammation-related disorders
- Sulfonylureas: Mouse studies showed anti-neuroinflammatory properties by targeting NLRP3 and modulating ERK/STAT3/NF-κB signaling
- Empagliflozin (SGLT2 inhibitor): Offered neuroprotection and helped neurovascular remodeling for cognitive function
- Insulin, metformin, thiazolidinediones: All have potential for repurposing against neuroinflammation
The shared pathway through NLRP3 inflammasome and IL-1β connects diabetes and neuroinflammation mechanistically.
Why it matters
Neurodegenerative diseases like Alzheimer's and Parkinson's have limited treatment options. People with diabetes have significantly higher risk of developing these conditions. If existing diabetes drugs — particularly GLP-1 agonists — can simultaneously address both metabolic and neuroinflammatory problems, millions of patients could benefit from treatments already proven safe.
How the study worked
Comprehensive narrative review synthesizing published research on the shared pathways between diabetes and neuroinflammation, and the potential for repurposing anti-diabetic medications for neurological conditions.
What this study cannot tell us
Most evidence for anti-neuroinflammatory effects comes from animal models, not human clinical trials. The review is narrative rather than systematic, potentially introducing selection bias. Drug concentrations needed for neuroprotection may differ from those used for diabetes management. Whether brain penetration is sufficient for all listed drugs is not fully addressed.
How to read the evidence
This is a narrative review synthesizing primarily preclinical evidence. While the biological rationale is well-supported, most neuroprotective findings come from animal studies and have not been confirmed in human neurology trials.
When this study was published
Published in 2025, this review reflects the current momentum toward repurposing diabetes drugs for neurological conditions, including ongoing clinical trials of GLP-1 agonists for Alzheimer's disease.
The bigger picture
The diabetes-neurodegeneration connection has become a major research focus, with clinical trials already testing liraglutide and semaglutide for Alzheimer's disease. This review reinforces the biological rationale for these trials and identifies additional diabetes drugs that could be tested for brain-protective effects.
Questions still open
- Do GLP-1 agonists provide enough brain penetration to meaningfully reduce neuroinflammation at standard diabetes doses?
- Should combination diabetes-neuroprotection therapy become standard for diabetic patients at risk of neurodegeneration?
- Which specific neurological conditions are most likely to benefit from each class of repurposed diabetes drug?
Common questions
Could my diabetes medication protect my brain?
What connects diabetes and brain diseases?
Read the original research
Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review.
3 Biotech, 15(9), 281
Citation
Blossom, Vandana; Ullal, Sheetal D; Rai, Rajalakshmi; D Souza, Melisha Michael; Kalluraya, P Gopal Govind; Dixit, Ayush; Jiji, P J; Murlimanju, B V. (2025). Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review.. 3 Biotech, 15(9), 281. https://doi.org/10.1007/s13205-025-04455-7